Arterial responses to infusion of glucagon-like peptide-1 in humans : A randomized trial study
Copyright © 2022 Elsevier Inc. All rights reserved..
Glucagon-like-peptide-1 (GLP-1) is an incretin hormone implicated in several metabolic and neurological disorders. GLP-1 induces vasodilation and increases blood flow in the peripheral circulation. Whether GLP-1 alters cerebral hemodynamics in humans is yet to be elucidated. In a crossover, double-blind, placebo-controlled, and randomized design, 21 healthy volunteers were assigned to receive intravenous GLP-1 infusion (2.5 pmol/kg/min) or placebo over 20 min on two different days separated by at least one week. We used a noninvasive, well-validated transcranial doppler (TCD) and ultrasound dermascan to reveal the effect of GLP-1 on intra- and extracerebral arteries. The mean blood flow velocity in the middle cerebral artery (VMCA), the diameter of the superficial temporal artery (STA) and radial artery (RA), and facial skin blood flow were measured. In addition, we documented headache and its associated symptoms during and after infusion. Twenty participants were included in the final analysis. We found no difference in the VMCA (P = 0.227), diameter of the STA (P = 0.096) and the RA (P = 0.221) and facial blood flow (P = 0.814) after GLP-1 compared to placebo. There were no differences in HR, SAT, EtCO2, or RF (P > 0.05) on the GLP-1 day compared to the placebo day. We found no differences in the incidence of headache after GLP-1 (n = 10) compared to placebo (n = 7) (P = 0.250). GLP-1 infusion did not affect cerebral hemodynamics and induce headache in humans. Further preclinical studies with validated methods are required to determine if intra - and extracerebral vasculature express GLP-1Rs in humans.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:150 |
|---|---|
| Enthalten in: |
Peptides - 150(2022) vom: 01. Apr., Seite 170736 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ghanizada, Hashmat [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 13.04.2022 Date Revised 13.04.2022 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.peptides.2022.170736 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33552009X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33552009X | ||
| 003 | DE-627 | ||
| 005 | 20231225230033.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.peptides.2022.170736 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1118.xml |
| 035 | |a (DE-627)NLM33552009X | ||
| 035 | |a (NLM)35017010 | ||
| 035 | |a (PII)S0196-9781(22)00002-X | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ghanizada, Hashmat |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Arterial responses to infusion of glucagon-like peptide-1 in humans |b A randomized trial study |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 13.04.2022 | ||
| 500 | |a Date Revised 13.04.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2022 Elsevier Inc. All rights reserved. | ||
| 520 | |a Glucagon-like-peptide-1 (GLP-1) is an incretin hormone implicated in several metabolic and neurological disorders. GLP-1 induces vasodilation and increases blood flow in the peripheral circulation. Whether GLP-1 alters cerebral hemodynamics in humans is yet to be elucidated. In a crossover, double-blind, placebo-controlled, and randomized design, 21 healthy volunteers were assigned to receive intravenous GLP-1 infusion (2.5 pmol/kg/min) or placebo over 20 min on two different days separated by at least one week. We used a noninvasive, well-validated transcranial doppler (TCD) and ultrasound dermascan to reveal the effect of GLP-1 on intra- and extracerebral arteries. The mean blood flow velocity in the middle cerebral artery (VMCA), the diameter of the superficial temporal artery (STA) and radial artery (RA), and facial skin blood flow were measured. In addition, we documented headache and its associated symptoms during and after infusion. Twenty participants were included in the final analysis. We found no difference in the VMCA (P = 0.227), diameter of the STA (P = 0.096) and the RA (P = 0.221) and facial blood flow (P = 0.814) after GLP-1 compared to placebo. There were no differences in HR, SAT, EtCO2, or RF (P > 0.05) on the GLP-1 day compared to the placebo day. We found no differences in the incidence of headache after GLP-1 (n = 10) compared to placebo (n = 7) (P = 0.250). GLP-1 infusion did not affect cerebral hemodynamics and induce headache in humans. Further preclinical studies with validated methods are required to determine if intra - and extracerebral vasculature express GLP-1Rs in humans | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Cerebral blood flow | |
| 650 | 4 | |a Doppler | |
| 650 | 4 | |a Extracranial | |
| 650 | 4 | |a Headache | |
| 650 | 4 | |a Human model | |
| 650 | 4 | |a Intra-extracerebral | |
| 650 | 4 | |a Migraine | |
| 650 | 4 | |a Neuropeptides | |
| 650 | 4 | |a Pain | |
| 650 | 4 | |a Vasodilation | |
| 650 | 7 | |a Glucagon-Like Peptide 1 |2 NLM | |
| 650 | 7 | |a 89750-14-1 |2 NLM | |
| 700 | 1 | |a Christensen, Rune Häckert |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Karagholi, Mohammad Al-Mahdi |e verfasserin |4 aut | |
| 700 | 1 | |a Elbahi, Fatima Azzahra |e verfasserin |4 aut | |
| 700 | 1 | |a Coskun, Hande |e verfasserin |4 aut | |
| 700 | 1 | |a Ashina, Messoud |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Peptides |d 1985 |g 150(2022) vom: 01. Apr., Seite 170736 |w (DE-627)NLM012597023 |x 1873-5169 |7 nnns |
| 773 | 1 | 8 | |g volume:150 |g year:2022 |g day:01 |g month:04 |g pages:170736 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.peptides.2022.170736 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 150 |j 2022 |b 01 |c 04 |h 170736 | ||